Abstract:
A compound of the following formula: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, X, Y, and Z are as defined herein. Also disclosed is a method for inhibiting actively of fibroblast activation protein or for treating cancer or inflammation conditions with such a compound.
Abstract:
A large-mode-area (LMA) optical fiber (10) that operates as a single-mode optical fiber. The optical fiber includes a core region (20) surrounded by an inner cladding (32), which in turn is surrounded by an outer cladding (40). The inner cladding includes at least one up-doped ring region (32R1). The ring region is configured to form a large attenuation differential between the higher-order modes and the fundamental mode so only that the fundamental mode remains traveling in the optical fiber. If necessary, the optical fiber can include a bend (10B) having a select “resonant” bend diameter (DB) that increases the relative attenuation of the fundamental and higher-order modes. The optical fiber supports an effective mode field diameter (MFD) of up to 40 μm to 50 μm. As a result, detrimental non-linear effects are suppressed, which allows the optical fiber to carry substantially more optical power than conventional LMA optical fibers. The LMA optical fiber is thus eminently suited for a number of optical-fiber-based applications calling for high optical power, such as fiber lasers and pump sources for wavelength conversion.
Abstract:
Generation of a cylindrically polarized light beam, and in particular, a hybrid-azimuthal-radial polarization beams, called HARP modes, generated from an input linearly polarized Gaussian beam using a spun optical waveguide device is taught. The HARP modes are comprised of hybrid-azimuthal polarization (HAP) and hybrid-radial polarization (HRP) superposition modes. These beams possess a non-zero local angular momentum density that is spatially varying and a zero total angular momentum.
Abstract:
Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
Abstract:
An optical fiber, comprising: (i) a core having a core center and a radius or a width a, (ii) a cladding surrounding the core, and (iii) at least one stress member situated proximate to the fiber core within the cladding, said stress member comprising silica co-doped with F and at least one dopant selected from the list consisting of: GeO2, P2O5, Y2O3, TiO2 and Al2O3, wherein distance b between the stress member and the core center satisfies the following equation: 1≦b/a
Abstract translation:1.一种光纤,包括:(i)具有芯中心和半径或宽度a的芯,(ii)围绕所述芯的包层,以及(iii)至少一个应力构件,位于所述包层内的所述纤维芯附近 所述应力部件包括与F共掺杂的二氧化硅和选自GeO2,P2O5,Y2O3,TiO2和Al2O3中的至少一种掺杂剂,其中应力部件与芯心之间的距离b满足以下等式:1&nlE ; b / a <2。
Abstract:
A detection system comprising: (i) an optical fiber, the optical fiber having (a) a length L≧1 km; (b) beat length between 10 m and 100 m; and (c) beat length uniformity over any distance of at least 100 m within the length L is characterized by standard deviation σ, where |σ|≦10 m; (ii) an OTDR coupled to the fiber and including (a) a radiation source providing pulsed radiation to the fiber, (b) a detection system capable of detecting radiation that is backscattered back through the fiber; and (iii) at least one polarizer situated between the fiber and the detector, such that the backscattered radiation passes through the polarizer before reaching the detector.
Abstract:
Multimode optical fiber is disclosed herein having a core surrounded by first and second annular cladding regions. The second annular cladding region has a maximum relative refractive index that is at least 0.05% higher than the minimum relative refractive index of the first annular cladding region.
Abstract:
The present invention relates generally to ophthamological drugs. More specifically, the invention relates to a method of modifying (derivatizing) ophthamological drugs so as to increase their penetration through the cornea. The invention also relates to drugs modified (derivatized) in accordance with the instant method and to the use of same in treating conditions associated with elevated intraocular pressure, particularly, glaucoma.
Abstract:
Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, x and y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes, including obesity, diabetes, modulation of feeding behavior and related metabolic syndrome.
Abstract:
Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.